Bromocriptine Review Article |
|
 |
|
 Bromocriptine (otherwise known as Cycloset and Parlodel) is a dopamine antagonist and also an ergoline derivative which is used for treating hyperprolactinemia, Type 2 Diabetes Mellitus, pituitary tumors, neuroleptic malignant syndrome, and Parkinson’s disease. This drug may also be used for treating illnesses due to pituitary problems, such as galactorrhea, acromegaly, female infertility, hypogonadism, and amenorrhea. Side effects of taking Bromocriptine may include vomiting, nausea, orthostatic hypotension, headaches,fatigue, worsening of liver problems, dry mouth, leg cramps, vasospasm which may lead to myocardial infarction, psychomotor excitation, hallucination, confusion, pulmonary fibrosis in high dosage, and in rare cases, seizure stroke or mental disorder in post-partum women. Contraindications include uncontrolled hypertension, hypertensive disorders of pregnancy, severe cardiovascular conditions, and serious mental disorders. Continue reading...
| Dosage |
Packing |
Price |
Add to basket |
| 2.5 mg |
30 tab ($0.50 per tab) |
USD 15.00 |
 |
| 2.5 mg |
90 tab ($0.46 per tab) |
USD 42.00 |
|
Bromocriptine or Bromocriptine mesylate is a powerful dopamine receptor agonist and ergoline derivative prescribed for diseases such as pituitary tumors, Parkinson’s disease and symptoms of hyperprolactinermia or high body level of prolactin which can cause amenorrhea, nipple discharge, infertility and hypogonadism. Bromcriptine is mainly used for conditions which involve tumors producing more than normal levels of natural body substances and has been shown to shrink these tumors. In conjunction with diet and exercise, it may also treat type 2 diabetes where blood sugar levels are caused by improper use of insulin in the body but not in type 1. Bromocriptine is taken orally either in capsule or tablet form and is only effective in creating results through symptom treatment but not disease cure itself.
Because of reports regarding adverse reactions from use of Bromocriptine, this drug was examined if efficiency and safety is better when administered through quick-release capsule form for diabetic patients. Out of 3,095 patients who were divided 2:1 to Bromocriptine to QR or placebo plus diet therapy and 2 antidiabetes medications, there were only reports from 8.6% and even 9.6% respectively for each group. This means that the effects are quite negligible in comparison to usual therapy for type 2 diabetes. There was also lower incidence of Cardiovascular disease.
Just recently, newer purposes for Bromocriptine are being examined upon. This includes its effectiveness as a form of therapy for visual and spatial recovery of previously stroke patients. In this type of condition, the “internal GPS” of the body may be altered most especially with severe cases causing the person’s perception on area of space as well as hand and body movement coordination to become impaired. It may also treat accompanying conditions of hemisensory neglect, hemispatial neglect, sensory neglect and somatosensory discrimination disorder. Bromocriptine is being compared in effectiveness with the usual treatment of Prism Adaptation Therapy.
References:
1. Gaziano M.D., M.P.H., J.M., Cincotta Ph.D., A.H., O’Connor, M.D., C.M. Ezrohki Ph.D., M. 2010. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes.
2. Barrett M.D., A.M. 2010. Comparing Prism Adaptation Therapy and Bromocriptine Medication for Spatial Neglect: Theoretical and Practical Outcomes.
|
|
Antiparkinson agents
 Bromocriptine Review Article
Buy here
|
|
My Basket
